In this segment on advanced renal cell carcinoma, Dr. McGregor explores the role of VEGFR TKI monotherapy in patients with favorable risk disease, where NCCN guidelines include both IO-TKI ...
This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not include a full text component.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results